Hepatitis Weekly articles from May 2009

Hepatitis Weekly archives from May 2009

Reports outline autoimmune hemolytic anemia study findings from J.F. Dufour and colleagues.
May 4, 2009... According to recent research published in the European Journal of Gastroenterology & Hepatology, " To describe the prevalence, main characteristics, and treatment of severe autoimmune cytopenias [autoimmune hemolytic anemia (AIHA), autoimmune...

Reports outline breast cancer study results from S. Dangelo et al.
May 4, 2009... "In the United States, over 3 million people are infected with hepatitis C virus (HCV), and over 200,000 women develop breast cancer annually. Yet, no published studies have investigated the tolerability of breast cancer-directed therapy among...

Data on hepatitis B virus discussed by researchers at University of Iowa.
May 4, 2009... According to recent research from the United States, "RNA interference (RNAi) can be an effective antiviral agent; however, overexpression of RNAi can be toxic through competition with the endogenous microRNA (miRNA) machinery. We used rational...

Data on hepatitis B virus reported by P. Manzini and co-researchers.
May 4, 2009... "Preliminary evidence of cases of acute occult hepatitis B virus (HBV) infection (OBI) has been recently reported in the literature. Furthermore, OBI definition has been the object of an international consensus conference," researchers in...

New data from V.P. Papadopoulos et al illuminate research in hepatitis B virus.
May 4, 2009... "The efficacy of pegylated interferon alfa-2b alone or in combination with lamivudine for the treatment of patients with hepatitis B e antigen (HBeAg) negative (-) chronic hepatitis B (CHB) is understudied. One hundred twenty-six patients with...

New hepatitis B virus research from University of Amsterdam outlined.
May 4, 2009... According to recent research from Netherlands, "Occult or latent hepatitis B virus (HBV) infection is defined as infection with detectable HBV DNA and undetectable surface antigen (HBsAg) in patients' blood. The cause of an overt HBV infection...

Recent findings from H. Fejza and co-authors highlight research in hepatitis B virus.
May 4, 2009... According to a study from Serbia, "Hepatitis is disease of the liver caused by the infectious and non-infectious agents. The aim of study was to analyze the prevalence of HBV and HCV among voluntary blood donors in Kosovo, during 2000-2003."...

Recent studies by F.F. Wang and co-authors add new data to hepatitis B virus findings.
May 4, 2009... According to a study from Shanghai, People's Republic of China, "Nucleoside/nucleotide analogues are a fundamental tool for the treatment of chronic hepatitis B virus (HBV). Sequential anti-HBV treatment might lead to the selection of...

Reports from Seoul National University advance knowledge in hepatitis B virus.(Report)
May 4, 2009... According to recent research from Seoul, South Korea, "A genome-wide in silico screening rendered the genes of phase II enzymes in the rat genome whose promoters contain the putative DNA elements interacting with CCAAT/enhancer binding protein...

Reports on hepatitis B virus findings from E. Nunez and co-researchers provide new insights.
May 4, 2009... "The role of preS domains of the hepatitis B virus (HBV) envelope proteins in the first steps of viral infection has been restricted to their implication in virus attachment to a putative hepatocyte receptor. In order to explore a fusion...

Findings in hepatitis C virus reported from B.M. Arendt and co-researchers.
May 4, 2009... "Hepatic fatty acid (FA) composition may influence steatosis development in patients with chronic hepatitis C (CHC). In a cross-sectional study, we compared the hepatic FA profile in hepatitis C patients with (n = 9) and without (n = 33)...

New data from Fourth Military Medical University illuminate research in hepatitis C virus.(Report)
May 4, 2009... "Hepatitis C virus (HCV) is a serious global health threat and current medical treatment options are limited. Interferon (IFN)-gamma is an important proinflammatory cytokine with antiviral activity," researchers in Xian, People's Republic of...

Report summarizes hepatitis C virus study findings from Tzu Chi University.(Report)
May 4, 2009... "Non-alcoholic fatty liver disease (NAFLD) is garnering increasing interest and acceptance as one of the most important causes of chronic liver disease. The aim of this study was to investigate the risk factors for NAFLD among selected...

Reports by S. Ujino and co-researchers describe recent advances in hepatitis C virus.(Report)
May 4, 2009... "The hepatitis C virus (HCV) is a major cause of chronic liver disease. Here, we report a new and effective strategy for inhibiting HCV replication using 17-allylaminogeldanamycin (17-AAG), an inhibitor of heat-shock protein 90 (Hsp90),"...

Reports from Karolinska University highlight recent research in hepatitis C virus.
May 4, 2009... According to recent research from Huddinge, Sweden, "Hepatitis C virus (HCV) effectively establishes persistent infection in human livers. The nonstructural (NS) 3/4A complex participates in this process by cleavage of interferon beta (IFN...

Reports summarize hepatitis C virus study results from Oregon Health & Science University.
May 4, 2009... "Assessment of liver histology has an important role in the management of chronic liver disease. It is not clear whether there are interobserver variabilities between hepatopathologists and general community pathologists," scientists in the...

Research from F.B. Garcia and co-researchers provides new data on hepatitis C virus.
May 4, 2009... "The aim of the present study was to outline the serological profile of hepatitis C among blood donors seen at the Uberaba Regional Blood Center, Hemominas Foundation, over the last 14 years. The frequency of hepatitis C was compared between...

Research from University of Illinois in the area of hepatitis C virus published.(Report)
May 4, 2009... According to recent research published in the Virology Journal, "Hepatitis C virus (HCV) encodes two transmembrane glycoproteins E1 and E2 which form a heterodimer. E1 is believed to mediate fusion while E2 has been shown to bind cellular...

Research on hepatitis C virus discussed by B. Bressler and co-researchers.
May 4, 2009... According to recent research from Toronto, Canada, "WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT center dot Obesity is a negative predictor of successful treatment in patients with chronic hepatitis C treated with peginterferon (PEG-IFN) and...

Research results from National Institutes of Health update knowledge of hepatitis C virus.
May 4, 2009... According to a study from the United States, "Early changes in hepatitis C virus (HCV) RNA levels were assessed in a large cohort of African American and white patients with chronic hepatitis C due to HCV genotype 1 who underwent therapy with...

Recent findings in hepatitis E virus described by researchers from Shanghai Jiao Tong University.
May 4, 2009... "In the present study, a genotype 4 HEV strain was identified in the fecal specimen from a seven months old infant with no symptom of hepatitis in Shanghai Children's hospital," scientists in Shanghai, People's Republic of China report (see...

New hepatocellular cancer findings from J. Shim and co-authors described.(Report)
May 4, 2009... "This study was conducted to assess the efficacy and safety of sorafenib monotherapy in clinical practice settings for Korean patients with hepatocellular carcinoma (HCC) related primarily to HBV infection. Medical records of 57 consecutive...

Researchers from Catholic University report on findings in ribosomes.
May 4, 2009... According to recent research published in the journal Nucleic Acids Research, "The HCV internal ribosome entry site (IRES) spans a region of similar to 340 nt that encompasses most of the 5' untranslated region (5'UTR) of the viral mRNA and the...

Newly Published Study Shows That Re-Treatment With Pegasys Peginterferon Alfa-2a Provides Hepatitis C Patients With a Second Chance for a Cure.(Clinical report)
May 4, 2009... New data published in a major peer-reviewed journal, Annals of Internal Medicine, show that re-treatment with Pegasys(R) (peginterferon alfa-2a) plus Copegus(R) (ribavirin) provides previously-treated hepatitis C patients a second...

Reports from University of Eastern Piedmont advance knowledge in chronic lymphocytic leukemia therapy.(Report)
May 4, 2009... Research findings, 'Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia,' are discussed in a new report. "Recent guidelines emphasise the risk of hepatitis B...

Research in the area of cirrhosis immunology reported from Second Military Medical University, Department of Laboratory Medicine.
May 4, 2009... New investigation results, 'Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population,' are detailed in a study published in Clinical &...

New findings in hepatitis B virus described from Southern Medical University, Department of Infectious Diseases.
May 4, 2009... Current study results from the report, 'Hepatitis B virus genotypes, subgenotypes, precore, and basal core promoter mutations in the two largest provinces of Pakistan,' have been published. "Hepatitis B virus (HBV) genotyping has been done in...

Reports on hepatitis B virus findings from Inova Fairfax Hospital provide new insights.
May 4, 2009... Research findings, 'Screening for hepatitis B, C and non-alcoholic fatty liver disease: a survey of community-based physicians,' are discussed in a new report. According to recent research from the United States, "Screening guidelines for...

New hepatitis B virus genetics research from G.T. Kumar and co-researchers described.(Report)
May 4, 2009... A report, 'Hepatitis B virus genotypes and hepatitis B surface antigen mutations in family contacts of hepatitis B virus infected patients with occult hepatitis B virus infection,' is newly published data in Journal of Gastroenterology and...

Data from G.B. Pant Hospital, Department of Gastroenterology advance knowledge in hepatitis C virus.
May 4, 2009... Investigators publish new data in the report 'Natural history of hepatic fibrosis progression in chronic hepatitis C virus infection in India.' "The rate of fibrosis progression per year can predict the time for the development of cirrhosis in...

New findings from University of Regensburg, Department of Internal Medicine I in the area of hepatitis C virus published.
May 4, 2009... Fresh data on hepatitis C virus are presented in the report 'Elevated adiponectin serum levels in patients with chronic alcohol abuse rapidly decline during alcohol withdrawal.' "Adiponectin is a circulating protein with hepatoprotective...

Findings from University of New South Wales in hepatitis C virus prevention reported.(Survey)
May 4, 2009... Researchers detail in 'Acceptability of hepatitis C virus testing methods among injecting drug users,' new data in hepatitis C virus. According to recent research published in the journal Drug and Alcohol Review, "The acceptability of testing...

Research results from V. Vlatkovic and co-authors update knowledge of hepatitis C virus therapy.
May 4, 2009... Data detailed in 'Malnutrition-inflammation complex syndrome and hepatitis C in maintenance hemodialysis patients' have been presented. "Protein-energy malnutrition and inflammation are among the leading causes of poor outcome in hemodialysis...

Researchers' work from Okayama University focuses on hepatitis C virus therapy.
May 4, 2009... Data detailed in 'Immunohistochemical staining of liver grafts with a monoclonal antibody against HCV-Envelope 2 for recurrent hepatitis C after living donor liver transplantation' have been presented. According to recent research from Shikata,...

Studies from Nihon University, Department of Pathology add new findings in the area of hepatitis E virus.(Report)
May 4, 2009... New research, 'Detection of hepatitis E virus RNA and genotype in Bangladesh,' is the subject of a report. According to a study from Tokyo, Japan, "Hepatitis E virus (HEV) in Bangladesh has not been adequately documented. We report HEV RNA and...

Researchers at Central South University, Department of Immunology publish new data on hepatocellular cancer immunology.
May 4, 2009... A new study, 'Increased expression of cyclooxygenase-2 and increased infiltration of regulatory T cells in tumors of patients with hepatocellular carcinoma,' is now available. According to recent research published in the journal Digestion,...

Recent studies from Tohoku University, Division of Gastroenterology add new data to hepatocellular cancer prevention.
May 4, 2009... Scientists discuss in 'Prevention of hepatocellular carcinoma complicating chronic hepatitis C' new findings in hepatocellular cancer. According to recent research published in the Journal of Gastroenterology and Hepatology, "Chronic hepatitis...

Reports outline life sciences study results from E.K. Manesis et al.
May 4, 2009... Current study results from the report, 'Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet.Greece cohort study,' have been published. According to recent research from Athens, Greece, "Interferon...

Data from Kaohsiung Medical University, Department of Preventive Medicine provide new insights into neutropenia therapy.(Report)
May 4, 2009... New research, 'Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice,' is the subject of a report....

Researchers from Oswaldo Cruz Institute report details of new studies and findings in the area of thrombocytopenia therapy.
May 4, 2009... Investigators publish new data in the report 'Autoimmune thrombocytopenia related to chronic hepatitis C virus infection.' According to a study from Rio de Janeiro, Brazil, "Since the identification of hepatitis C virus (HCV) in 1989 as a...

Reports outline alcoholism research from A. Pares and colleagues.(Report)
May 4, 2009... " The aim of this study was to assess the effects of albumin dialysis on hepatic encephalopathy and circulating levels of amino acids in severe alcoholic hepatitis. The study was carried out in nine patients with severe alcoholic hepatitis and...

Studies from University of Bern reveal new findings on alcoholism.
May 4, 2009... "NAFLD (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis) are of increasing importance, both in connection with insulin resistance and with the development of liver cirrhosis. Histological samples are still the 'gold...

Studies from M. Pellegrinotti et al have provided new data on lung cancer.
May 4, 2009... "To report a case of erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly patient with lung adenocarcinoma and diabetes mellitus. SUMMARY: A 77-year-old man with stage IIIB lung adenocarcinoma was treated with...

Can-Fite BioPharma to Initiate Phase I/II Clinical Trial With CF102 for the Treatment of Liver Cancer.
May 4, 2009... Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange announced that, following the approval by the Israel Ministry of Health and Rabin MC Ethics Committee, a phase I/II clinical trial with CF102 for the...

Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting.
May 4, 2009... Valeant Pharmaceuticals (NYSE:VRX) announced that results from the week-60 analysis for its Phase IIb dose-finding clinical trial for taribavirin, a prodrug of ribavirin which is in development for the treatment of chronic hepatitis C in...

First evidence for DNA-based vaccination against chronic hepatitis C.
May 4, 2009... The first-proof-of-concept for a DNA-based therapeutic vaccination against chronic hepatitis C was announced at EASL 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark (see also European...

Hadasit to Assign to Immuron an Oral Immune Modulation Technology Developed at Hadassah Medical Center.
May 4, 2009... Hadasit, the technology transfer company of the Hadassah Medical Organization, and Immuron, a biopharmaceutical company, announced an agreement whereby Immuron will assign from Hadasit a novel oral immune modulation technology that was...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients.
May 4, 2009... Anadys Pharmaceuticals, Inc. (NASDAQ:ANDS) announced that ANA598, the Company's investigational non-nucleoside polymerase inhibitor, demonstrated potent antiviral activity at all dose levels and was well tolerated in a Phase Ib study in which...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C.
May 4, 2009... Pharmasset, Inc. (NASDAQ:VRUS) and Roche (Roche SWX: RO, ROG; Pink Sheets: RHHBY) announced that the first patient has been dosed in a Phase IIb study of R7128, the nucleoside polymerase inhibitor most advanced in development for the treatment...

Presidio Pharmaceuticals, Inc. to Present Data on their Lead Hepatitis C Virus NS5A Inhibitor Program at the European Association for the Study of the Liver EASL Conference.(Conference news)
May 4, 2009... Presidio Pharmaceuticals, Inc. announced that Dr. Richard Colonno, the company's Chief Scientific Officer, would be presenting data on their hepatitis C virus NS5A inhibitor program at the 44th Annual Meeting of the European Association for the...

Vertex Pharmaceuticals Reviews First Quarter Business Progress and Reports First Quarter 2009 Financial Results.(Financial report)
May 4, 2009... Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reviewed first quarter 2009 business and clinical achievements and reported consolidated financial results for the quarter ended March 31, 2009 (see also Vertex Pharmaceuticals...

Researchers from University of Navarra detail new studies and findings in the area of hepatitis.
May 11, 2009... "Oncostatin M (OSM) is released together with type I interferon (IFN) by activated dendritic cells, suggesting a concerted action of these cytokines in the biological response against infection. We found that OSM increases the antiviral effect...

Research in the area of hepatitis B virus reported from Shandong University.
May 11, 2009... "T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) has been reported to participate in the pathogenesis of inflammatory diseases. However, whether Tim-3 is involved in hepatitis B virus (HBV) infection remains unknown,"...

Studies from K. Dallmeier and co-researchers in the area of hepatitis B virus published.
May 11, 2009... According to recent research from Freiburg, Germany, "Hepadnaviruses, including hepatitis B virus (HBV), a highly relevant human pathogen, are small enveloped DNA viruses that replicate via reverse transcription. All hepadnaviruses display a...

Findings from M. Kita and co-authors broaden understanding of hepatitis C virus.
May 11, 2009... According to recent research from Osaka, Japan, "Nine anti-HCV antibody screening reagents currently used in Japan were investigated for diagnostic utility. The results using sera from 500 subjects and two series of anti-HCV seroconversion...

Findings from N. Nakamoto and co-authors broaden understanding of hepatitis C virus.
May 11, 2009... According to a study from the United States, "Viral persistence is associated with hierarchical antiviral CD8 T cell exhaustion with increased programmed death-1 (PD-1) expression. In HCV persistence, HCV-specific CD8 T cells from the liver...

New findings from E. Babaylova and co-authors in the area of hepatitis C virus published.
May 11, 2009... According to recent research from Russia, "The 5-untranslated region of the hepatitis C virus (HCV) RNA contains a highly structured motif called IRES (Internal Ribosome Entry Site) responsible for the cap-independent initiation of the viral...

New hepatitis C virus research reported from University of Washington, Medical Department.
May 11, 2009... According to recent research published in the journal Plos Pathogens, "The mechanisms of liver injury associated with chronic HCV infection, as well as the individual roles of both viral and host factors, are not clearly defined. However, it is...

New hepatitis C virus study findings recently were published by H. Li and co-researchers.
May 11, 2009... 'The HCV RNA-dependent RNA polymerase has emerged as one of the key targets for novel anti-HCV therapy development. Herein. we report the optimization of the dihydropyrone series inhibitors to improve compound aqueous solubility and reduce...

Recent findings in hepatitis C virus described by K.X. Chen and colleagues.
May 11, 2009... "The hepatitis C virus (HCV) infection is a leading cause of chronic liver disease. The moderate efficacy along with side effects of the current pegylated interferon and ribavirin combination therapy underscores the need for more effective and...

Reports from Hiroshima University highlight recent research in hepatitis C virus.(Clinical report)
May 11, 2009... "To compare the efficacy and safety of pegylated interferon (PEG-I) at 1 and 1.5 mu g/kg, and in combination with ribavirin (RBV) for 24 weeks in naive Japanese patients infected with hepatitis C virus genotype 2. The present study was an...

Reports summarize hepatitis C virus study results from Yale University.
May 11, 2009... "Nonstructural protein 3 (NS3) is an essential replicative component of the hepatitis C virus (HCV) and a member of the DExH/D-box family of proteins. The C-terminal region of NS3 (NS3hel) exhibits RNA-stimulated NTPase and helicase activity,...

Research findings from University of Erlangen, Medical Department update understanding of hepatitis C virus.
May 11, 2009... "The cumulative dosage of ribavirin per kilogram of body-weight prevents relapse and thus is a significant predictor of sustained virological response (SVR). Comparison of peginterferon (peg-IFN) alfa-2b/ribavirin and peg-IFN alfa-2a/ribavirin...

Research from University of Alberta yields new findings on hepatitis C virus.
May 11, 2009... According to a study from Edmonton, Canada, "Hepatitis C virus (HCV) is a blood-borne pathogen and a major cause of liver disease worldwide. Gene expression profiling was used to characterize the transcriptional response to HCV H77c infection."...

Studies from F.J. Eng et al have provided new data on hepatitis C virus.(Report)
May 11, 2009... According to a study from the United States, "The hepatitis C virus (HCV) core gene is more conserved at the nucleic acid level than is necessary to preserve the sequence of the core protein, suggesting that it contains information for...

Studies from University of Lyon provide new data on hepatitis C virus.
May 11, 2009... "HCV entry into cells is a multi-step and slow process. It is believed that the initial capture of HCV particles by glycosaminoglycans and/or lipoprotein receptors is followed by coordinated interactions with the scavenger receptor class B type...

Studies from University of Rome reveal new findings on hepatitis C virus.
May 11, 2009... "CD4(+)CD25(+)Foxp3(+) Tregs suppress autoimmune responses. In addition, they limit T cell responses during chronic infection, thereby minimizing T cell-dependent immunopathology," scientists in Rome, Italy report (see also Hepatitis C Virus)....

Research on hepatocellular cancer discussed by scientists at University of Hong Kong.
May 11, 2009... According to a study from Hong Kong, People's Republic of China, "Hepatocellular carcinoma (HCC) is an aggressive liver cancer but clinically validated biomarkers that can predict natural history of malignant progression are lacking. The...

Data on neuropathy detailed by N. Kabbaj and co-authors.
May 11, 2009... "Ophthalmological, complications with interferon therapy are rare, usually mild and reversible, and do not require the withdrawal of antiviral treatment," scientists in Rabat, Morocco report (see also Neuropathy). "Anterior ischemic optic...

Research on hepatitis A virus detailed by scientists at Centro de Investigacion en Alimentacion y Desarrollo.(Report)
May 11, 2009... Data detailed in 'Detection and characterization of hepatitis A virus and Norovirus in estuarine water samples using ultrafiltration--RT-PCR integrated methods' have been presented. "Waterborne outbreaks of hepatitis A and Norovirus disease...

Research from Yonsei University yields new data on acute hepatitis.
May 11, 2009... "Gallbladder wall thickening (GWT) is often observed in patients with acute hepatitis (AH). However, little is known regarding the relationship between AH and GWT," scientists writing in the Journal of Clinical Ultrasound report (see also Acute...

Studies from A. Rana and colleagues reveal new findings on hemolysis.
May 11, 2009... "To study the causes of maternal mortality in two consecutive five year periods over a decade (1997-2001/2002-2006) in a university hospital. A maternal mortality over 10 years (1997-2006) was analyzed prospectively from the...

New hepatic disease findings from Y.H. Tsai and co-researchers published.(Report)
May 11, 2009... According to recent research from Taiwan, "Vibrio species are a rare cause of necrotizing soft-tissue infections and primary septicemia, which are likely to occur in patients with hepatic disease, diabetes, adrenal insufficiency, and...

Avila Presents Preclinical Data on a Novel, Orally-Available, Protease Inhibitor, AVL181, for Hepatitis C Infection at EASL 2009 Meeting.
May 11, 2009... Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, for the first time presented results of preclinical studies on its small molecule Hepatitis C Virus (HCV)...

Added anti-viral improves response, halves duration of hepatitis C treatment.(Clinical report)
May 11, 2009... The addition of the anti-viral drug telaprevir to a standard treatment for hepatitis C can shorten the duration of therapy and increase the number of patients who can be cured of their disease, according to the results of study coordinated by...

Dynavax Announces First Quarter 2009 Financial Results.(Financial report)
May 11, 2009... Dynavax Technologies Corporation (Nasdaq: DVAX) reported financial results for the first quarter ended March 31, 2009 (see also Dynavax Technologies Corporation). Over the coming year, Dynavax intends to advance the development of its...

Dynavax Presents Additional Phase 3 Data for HEPLISAV[TM] Hepatitis B Vaccine at EASL Medical Conference.
May 11, 2009... Dynavax Technologies Corporation (Nasdaq:DVAX) announced the oral presentation of additional Phase 3 clinical data for HEPLISAV™ hepatitis B vaccine in a session for late-breaking abstracts at the 44th Annual Meeting of the European...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen.
May 11, 2009... Roche, InterMune, Inc. (NASDAQ:ITMN) and Pharmasset (NASDAQ:VRUS) announced the first results from their innovative, interferon-free regimen of direct acting antiviral (DAA) combination therapy for the treatment of patients chronically infected...

Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C.(Financial report)(Clinical report)
May 11, 2009... Human Genome Sciences, Inc. (NASDAQ:HGSI) reported that the final results of two pivotal Phase 3 trials demonstrate that Albuferon(R) (albinterferon alfa-2b) met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) in the...

InterMune Reports First Quarter 2009 Financial Results and Business Highlights.(Financial report)
May 11, 2009... InterMune, Inc. (NASDAQ:ITMN) announced results from operations for the first quarter ended March 31, 2009. InterMune reported a net loss for the first quarter of 2009 of $42.0 million, or $1.03 per share, compared with a net loss of $29.1...

Integrated Environmental Technologies, Ltd. announces MRSA - Specific EPA Registration of EcaFlo[R] Excelyte[R].
May 11, 2009... Integrated Environmental Technologies, Ltd. (OTCBB: IEVM) and Benchmark Research & Technology (BRT) announced that the U.S. EPA has approved EcaFlo® Anolyte (trademarked Excelyte®), as a registered and effective biocide against MRSA...

Biolex presents Locteron US Phase 2a hepatitis C data at EASL.
May 11, 2009... Biolex Therapeutics, Inc. announced that the results from its United States Phase 2a clinical trial (the "PLUS" trial) of Locteron® will be presented today at the 44th Annual Meeting of the European Association for the Study of the Liver...

GeneNews to conduct joint project funded by MYR 5 million grant from Malaysian government.
May 11, 2009... GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, announced that it will undertake a two-year joint project to develop blood-based...

Report Finds an Alarming Number of Chronically Ill Patients - Over 93 Percent - Reporting Medical Debt Crisis Issues in 2008 Have Some Form of Insurance.(Report)
May 11, 2009... Patient Advocate Foundation (PAF) - a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial stability relative to...